| Literature DB >> 34292649 |
Catrina Mugglin1, Delia Kläger1, Aysel Gueler1, Fiona Vanobberghen2,3,4, Brian Rice2, Matthias Egger1,5,6.
Abstract
INTRODUCTION: The HIV care cascade examines the attrition of people living with HIV from diagnosis to the use of antiretroviral therapy (ART) and suppression of viral replication. We reviewed the literature from sub-Saharan Africa to assess the definitions used for the different steps in the HIV care cascade. <br> METHODS: We searched PubMed, Embase and CINAHL for articles published from January 2004 to December 2020. Longitudinal and cross-sectional studies were included if they reported on at least one step of the UNAIDS 90-90-90 cascade or two steps of an extended 7-step cascade. A step was clearly defined if authors reported definitions for numerator and denominator, including the description of the eligible population and methods of assessment or measurement. The review protocol has been published and registered in Prospero. RESULTS AND DISCUSSION: Overall, 3364 articles were screened, and 82 studies from 19 countries met the inclusion criteria. Most studies were from Southern (38 studies, 34 from South Africa) and East Africa (29 studies). Fifty-eight studies (71.6%) were longitudinal, with a median follow-up of three years. The medium number of steps covered out of 7 steps was 3 (interquartile range [IQR] 2 to 4); the median year of publication was 2015 (IQR 2013 to 2019). The number of different definitions for the numerators ranged from four definitions (for step "People living with HIV") to 21 (step "Viral suppression"). For the denominators, it ranged from three definitions ("Diagnosed and aware of HIV status") to 14 ("Viral suppression"). Only 12 studies assessed all three of the 90-90-90 steps. Most studies used longitudinal data, but denominator-denominator or denominator-numerator linkages over several steps were rare. Also, cascade data are lacking for many countries. Our review covers the academic literature but did not consider other data, such as government reports on the HIV care cascade. Also, it did not examine disengagement and reengagement in care. <br> CONCLUSIONS: The proportions of patients retained at each step of the HIV care cascade cannot be compared between studies, countries and time periods, nor meta-analysed, due to the many different definitions used for numerators and denominators. There is a need for standardization of methods and definitions.Entities:
Keywords: ART outcomes; HIV; care cascade; sub-Saharan Africa; virological suppression
Year: 2021 PMID: 34292649 PMCID: PMC8297382 DOI: 10.1002/jia2.25761
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Figure 1Cascade steps and denominators used for each step. The figure shows the denominators and numerators and their connection adapted from the WHO framework for cross‐sectional and longitudinal studies. *Steps of the 90‐90‐90 cascade. VS, viral suppression.
Figure 2Flowchart of study selection.
Characteristics of 82 published studies reporting on the HIV care cascade in sub‐Saharan Africa
| Characteristic | |
|---|---|
| Year of publication | 2015 (2013 to 2019) |
| No. of people included | 1776 (559 to 7536) |
| Study design | |
| Longitudinal study | 58 (71.6%) |
| Cross‐sectional study | 18 (22.2%) |
| Mixed design | 5 (6.25) |
| No. of steps covered | 3 (2 to 4) |
| Duration of follow‐up (years) | 3 (2 to 6) |
| Total no. of countries included | 19 |
| Region | |
| Central Africa | 4 (4,9%) |
| East Africa | 29 (35.4%) |
| Southern Africa | 38 (46.3%) |
| West Africa | 7 (8.5%) |
| Multi‐regional study | 4 (4.9%) |
| No. of sites | 2 (1 to 15) |
| No. of studies at national level | 2 (2.4%) |
| Data collection methods | |
| Routine clinical records | 61 (74.4%) |
| Questionnaires | 35 (42.7%) |
| Blood samples collected specifically for study | 33 (40.2%) |
| Clinical records extracted from | |
| Paper files only | 6 (9.8%) |
| Paper and electronic files | 10 (16.4%) |
| Electronic files only | 28 (45.9%) |
| Not reported | 17 (27.8%) |
Median (interquartile range) or number (%) are shown.
Studies combining cross‐sectional and longitudinal datasets
data for the 58 longitudinal studies
studies not reporting on national level or mobile testing (N = 52)
61 studies where clinical records were used.
Reporting and definitions provided on seven HIV care cascade steps in 82 published studies
| HIV care cascade step | Description | Study design | No. of studies reporting on step (% of 82 studies) | No. of studies reporting definition for numerator and denominator (% of studies reporting on step) | No. of definitions used for numerator | No. of definitions used for denominator | |
|---|---|---|---|---|---|---|---|
| Description of definitions | Description of definitions | ||||||
| 1 | People living with HIV | The proportion of people testing positive for HIV |
10 Cross‐sectional 3 Longitudinal 2 Mixed study design | 15 (18%) | 14 (93%) | 4 | 5 |
|
People tested HIV positive in study through: HTC rollout Outreach campaign Home‐based testing and counselling People tested HIV positive OR self‐reporting being HIV positive |
People tested for HIV: Adult residents of a high prevalence community Participants of testing campaign Participants of home‐based counselling and testing (HBCT) in a survey among resident adults Random sample of population Participants in cross‐sectional survey | ||||||
| 2 | Diagnosed and aware of their status | The proportion of people living with HIV who are aware of their status |
10 Cross‐sectional 10 Longitudinal 4 Mixed study design | 24 (29%) | 19 (79%) | 5 | 3 |
|
Self‐reported to be HIV positive Awareness of HIV‐positive status either through VCT at the sero‐survey or through self‐reporting. HIV infection assessed through: Clinical records Having a previous positive test Having a previous HIV related clinical visit |
All participants testing positive for HIV Everyone attending HIV testing Population of testing area | ||||||
| 3 | Linked to pre‐ART care | The proportion of people living with HIV linked to care |
10 Cross‐sectional 15 Longitudinal 3 Mixed study design | 28 (34%) | 24 (86%) | 5 | 6 |
|
Self‐reported measures: Clinical visit Eligibility assessment for ART performed Assessed through clinical records: Recorded clinical visit Eligibility assessment for ART performed Patient engages with HIV‐related health care (clinic visit, registration in clinic, CD4 cell count, VL measurement, recorded ART start) Time point of measurement: 1 to 12 months since diagnosis |
All participants testing HIV positive Participants newly infected with HIV (not necessarily diagnosed) Participants newly diagnosed with HIV Participants HIV positive and aware of their status Participants reporting a positive HIV self‐test HIV‐positive participants not on ART at baseline, reporting never having initiated ART | ||||||
| 4 | Retention in pre‐ART care | The proportion of people linked to HIV care who are retained in pre‐ART care |
6 Cross‐sectional 13 Longitudinal | 19 (23%) | 12 (63%) | 8 | 10 |
|
Self‐reported measures: Clinical visit Eligibility assessment completed Ascertained through clinical records: Clinical visit Eligibility assessment completed Patient engages with formal healthcare sector for HIV‐related healthcare (HIV clinic visit, registration in clinic, CD4 cell count, VL measurement, recorded ART start) Time point of measurement: 1 to 12 months since diagnosis Definitions that were not further specified but allowed for interpretation of findings: "not eligible for ART or eligible but retained in care," "retained in the HIV care cascade" |
Participants enrolled in study Participants newly diagnosed with HIV All participants testing HIV positive Participants reporting a positive HIV self‐test Participants HIV positive and aware of their status HIV‐positive participants not on ART at baseline HIV positive never reporting ART initiation Patients enrolled in care Participants who present for at least one follow‐up visit Participants with available CD4 cell count and VL measurements | ||||||
| 5 | ART initiation | The proportion of people linked to pre‐ART care who initiated ART |
3 Cross‐sectional 32 Longitudinal 4 Mixed study design | 39 (48%) | 25 (64%) | 9 | 9 |
|
Assessed as: Self‐reported use of ART Clinical records, clinically confirmed ART initiation date Laboratory confirmation of ART in blood samples Imputed based on documented creatinine‐measurement (which is performed prior to initiation of Tenofovir) Not specified how initiation was assessed Time point of measurement: Months since eligibility criteria met (range: 3 to 12 months) Months since diagnosis (range: 1 to 12 months) At the end of study period (2.5 to 10 years) Definition that was not further specified: "Participants initiating ART" |
PLWH: PLWH enrolled in the study All participants testing HIV positive and receiving their result Participants with confirmed HIV‐positive status Newly diagnosed with HIV HIV‐positive study participants willing to share their status Participants ever linked to care Enrolled in study with available VL Eligible for ART: Participants eligible for ART based on CD4 cell count or clinical staging Participants eligible for ART and linked to care Newly diagnosed with HIV and eligible for ART | ||||||
| 6 | Retention on ART | The proportion of people on sustained ART who initiated ART |
13 Cross‐sectional 29 Longitudinal 4 Mixed study design | 46 (56%) | 34 (74%) | 12 | 8 |
|
Self‐reported measures: Clinic visit Showing medication to study nurse ART use, including missed doses Ascertained through: Clinical records Laboratory testing (ART drug levels; “HIV related laboratory testing” not further specified) Pharmacy records/refills Pill counts Time points for measurement for longitudinal studies: On ART for: 6 month, 12 months, 2 years, 3 years At the end of the study period: 7 years, 10 years Definitions that were not further specified: "Currently on ART," “active on ART,” “self‐reported retention in care” |
Participants self‐reporting being HIV positive (not necessarily confirmed through a test) Participants with laboratory confirmed HIV status and reporting to have known that they are HIV positive Participants newly diagnosed with HIV Participants starting ART (self‐reported or assessed through clinical records) Participants currently receiving ART at clinics Participants that tested HIV positive (in study, random sample, cross‐sectional survey) HIV positive and available VL Participants currently in HIV care (visited a clinic within the past 6 months) | ||||||
| 7 | Viral suppression | The proportion of all people receiving ART who have suppression of HIV replication |
16 Cross‐sectional 32 Longitudinal 4 Mixed study design | 52 (63%) | 48 (92%) | 21 | 14 |
|
Definition of viral suppression ranged from <25 to <5000 copies/mL. Threshold was not explicitly stated in one study. Time points at which viral suppression was assessed ranged from 1 month on ART to 10 years on ART. Time point was not specified in 18 studies |
HIV‐positive participants who consented to a second blood sample all HIV‐positive participants newly diagnosed, linked to care, initiated ART self‐reported ART use HIV‐positive participants who self‐reported regularly accessing an ARV clinic testing ART drug positive Patients with available VL measurements at 12 months, at 10 years Patients on ART with available VL at 6 month, 12 month, 2 years, 4 years, at the end of the study period Definitions that were not further specified: “Participants initiating ART” |
Correspond to UNAIDS 90‐90‐90 targets
cross‐sectional and longitudinal component.
Figure 3Cascade steps and denominators used for each step in 82 studies. Bubbles represent numerators, connectors point to the corresponding denominator.